Chicago Partners Investment Group LLC Immuno Gen, Inc. Transaction History

Chicago Partners Investment Group LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 23, 2024	BUY	$12.46 - $29.95 $147,937 - $355,596	11,873 New	11,873 $352,000
Q1 2023 Apr 26, 2023	BUY	$3.67 - $4.92 $11,288 - $15,133	3,076 Added 13.73%	25,482 $97,000
Q4 2022 Feb 09, 2023	SELL	$4.55 - $6.31 $1,765 - $2,448	-388 Reduced 1.7%	22,406 $111,000
Q3 2022 Nov 09, 2022	BUY	$4.48 - $6.47 $9,403 - $13,580	2,099 Added 10.14%	22,794 $130,000
Q2 2022 Aug 04, 2022	SELL	$3.15 - $5.76 $507 - $927	-161 Reduced 0.77%	20,695 $98,000
Q1 2022 May 20, 2022	SELL	$4.26 - $7.48 $6,551 - $11,504	-1,538 Reduced 6.87%	20,856 $73,000
Q4 2021 Feb 15, 2022	SELL	$4.75 - $7.5 $38,109 - $60,172	-8,023 Reduced 26.38%	22,394 $124,000
Q3 2021 Nov 12, 2021	SELL	$5.02 - $6.59 $2,610 - $3,426	-520 Reduced 1.68%	30,417 $172,000
Q2 2021 Aug 02, 2021	BUY	$5.79 - $8.6 $37,403 - $55,556	6,460 Added 26.39%	30,937 $172,000
Q1 2021 Apr 28, 2021	BUY	$6.5 - $10.53 $159,100 - $257,742	24,477 New	24,477 $199,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Chicago Partners Investment Group LLC, based on Form 13F filings with the SEC.

Stay updated on Chicago Partners Investment Group LLC with notifications on news.